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Background: Coronary computed tomography angiography (CTA) is the preferred primary diagnostic 
modality when examining patients with low to intermediate pre-test probability of coronary artery disease 
(CAD). Only 20-30% of these have potentially obstructive CAD. Because of the relatively poor positive 
predictive value of coronary CTA, unnecessary invasive coronary angiographies (ICA) are conducted with 
the costs and risks associated with the procedure. Hence, an optimized diagnostic CAD algorithm may 
reduce the numbers of ICAs not followed by revascularization.  
The Dan-NICAD 2 study has three equivalent main aims: 1) to examine the diagnostic precision of a sound 
based diagnostic algorithm, The CADScor®System (Acarix A/S, Denmark), in patients with a low to 
intermediate pre-test risk of CAD referred to a primary examination by coronary CTA. We hypothesize that 
the CADScor®System provides better stratification prior to coronary CTA than clinical risk stratification 
scores alone. 2) to compare the diagnostic accuracy of 3 Tesla cardiac magnetic resonance imaging (3T 
CMRI), 82Rubidium positron emission tomography (82Rb-PET) and CT-derived fractional flow reserve 
(FFRCT) in patients where obstructive CAD cannot be ruled out by coronary CTA using ICA fractional flow 
reserve (FFR) as reference standard. 3) to compare the diagnostic performance of quantitative flow ratio 
(QFR) and ICA-FFR in patients with low to intermediate pre-test probability of CAD using 82Rb-PET as 
reference standard. 
Methods/design: Dan-NICAD 2 is a prospective, multicenter, cross-sectional study including approximately 
2,000 patients with low to intermediate pre-test probability of CAD and without previous history of CAD. 
Patients are referred to CTA because of symptoms suggestive of CAD, as evaluated by a cardiologist. Patient 
interviews, sound recordings, and blood samples are obtained in connection with the coronary CTA. If 
coronary CTA does not rule-out obstructive CAD, patients will be examined by both 3T CMRI, 82Rb-PET, 
FFRCT, ICA and FFR. Reference standard is ICA-FFR. Obstructive CAD is defined as an FFR ≤0.80 or as 
high-grade stenosis (>90 % diameter stenosis) by visual assessment.  
Diagnostic performance will be evaluated as sensitivity, specificity, predictive values, likelihood ratios, 
calibration, and discrimination. Enrolment started January 2018 and is expected to be completed by June 
2020. Patients are followed for 10 years after inclusion.  
Discussion: The results of the Dan-NICAD 2 study are expected to contribute to the improvement of 
diagnostic strategies for patients suspected of CAD in three different steps; risk-stratification prior to 




Study registration: Clinicaltrials.gov identifier, NCT03481712. Registered on January 25th 2018.   
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1. Background 
An increasing number of patients are referred for evaluation of suspected obstructive coronary artery disease 
(CAD). Coronary computed tomographic angiographies (CTA) is currently recommended by the National 
Institute for Health and Care Excellence (NICE) as the initial diagnostic test for patients with stable CAD 
[1]. Of the patients examined, results from large databases show that coronary CTA excludes cardiovascular 
disease in 70-80% with an excellent negative predictive value of more than 95%.[2] However, coronary CTA 
alone has consistently proven to have a low positive predictive value, thus often overestimating the severity 
of CAD, especially in patients with moderate to severe coronary calcification.[3] Following coronary CTA, 
patients are frequently investigated with invasive coronary angiography (ICA) and fractional flow reserve 
(FFR). In this group, ICA often shows no obstructive CAD [4-6] and revascularization is not required. ICA 
still adds major costs and imply minor but not negligible risks of adverse events. The outlined issues raise the 
question of whether it is possible (1) to make a more precise stratification based on probability and 
consequently better patient selection prior to coronary CTA and (2) to reduce the number of patients referred 
for unnecessary ICAs and intracoronary flow assessments following CTA.  
Acoustic detections of coronary stenosis from automatically recorded and analyzed heart sounds is a newly 
developed technology potentially useful for pre-test probability stratification before e.g. coronary CTA.[7] 
One of these devices, the CADScor®System (Acarix A/S, Denmark), extracts 8 acoustic features related to 
turbulent blood flow emerging from stenosed coronary segments as well as other cardiac sounds 
characteristic to CAD.[8, 9] In the Dan-NICAD 2 study, we will investigate the diagnostic performance of 
the most recently developed algorithm in the CADScor®System. 
In patients with suspicion of coronary stenosis detected by coronary CTA, current guidelines recommend 
performing functional tests to verify the presence of inducible myocardial ischemia to reduce unnecessary 
ICAs.[10] Diagnostic accuracy of secondary non-invasive imaging with single photon emission computed 
tomography (SPECT) and 1.5 Tesla cardiac magnetic resonance imaging (CMRI) were investigated in the 
Dan-NICAD 1 trial.[11, 12] In Dan-NICAD 2, we intend to investigate the diagnostic accuracy of more 
advanced non-invasive myocardial perfusion imaging tests such as 82Rubidium positron emission 
tomography (82Rb-PET) and 3 Tesla (3T) CMRI. For both modalities, a high diagnostic accuracy was 
demonstrated in symptomatic patients with high probability of obstructive CAD.[13] However, the 
diagnostic accuracy has yet not been examined when these tests are used as second-line investigation after 
coronary CTA.  
An alternative way to increase the diagnostic accuracy of coronary CTA and thus avoid unnecessary 
downstream testing is to utilize the ability to extract physiological information from the anatomical coronary 
CTA images. This technique - known as CT-derived fractional flow reserve (FFRCT) - has become 
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increasingly popular and has in preliminary studies shown promising results.[14, 15] Several companies are 
currently developing software for these analyses but the utilization of this technique has so far predominantly 
been tested in selected populations. In these selected cohorts, FFRCT shows good diagnostic accuracy 
compared to the gold standard pressure-based ICA-FFR. Nonetheless, head to head comparison studies 
against non-invasive myocardial perfusion imaging tests are sparse.  
Quantitative flow ratio (QFR) is a novel pressure wire-free approach for fast computation of FFR with 
potential to increase the global use of physiological lesion assessment.[16, 17] QFR is superior to traditional 
assessment of intermediate coronary lesions (QCA) and can be computed in-procedure within the same time 
as conventional wire-based approaches.[18] However, disagreement between FFR and QFR is identified in 
up to 20% of all measurements.[18] In Dan-NICAD II, the QFR-FFR disagreement is characterized by 
comparing paired QFR and FFR to 82Rb-PET scan as a third test of reference.  
This study has 3 main objectives. 1) to examine the diagnostic precision of a sound based diagnostic 
algorithm, the CADScor®System, in patients with a low to intermediate pre-test risk of CAD referred to a 
primary examination by coronary CTA. We hypothesize that the CADScor®System provides better 
stratification prior to coronary CTA than clinical risk stratification scores alone. 2) to determine the 
diagnostic accuracy of FFRCT, 3T CMRI and 82Rb-PET in patients where obstructive CAD cannot be ruled 
out by coronary CTA. 3) to compare the diagnostic precision of QFR and FFR in patients with low to 















2.1 Study design 
This study is an investigator-initiated, prospective, multicenter study. The study examines subjects without 
known CAD, who are referred for cardiac evaluation following symptoms suggestive of CAD. Study 
subjects are recruited at hospitals in the Central Denmark Region. This study will include approximately 
2,000 patients with low to intermediate pre-test probability of CAD. All patients will provide their clinical 
history including detailed information about chest discomfort, will have a CAD-score examination, blood 
sampled for a biobank and finally undergo a non-enhanced and contrast-enhanced coronary CTA. It is 
expected that 20-23% of patients will have coronary stenosis suspected at the coronary CTA. These patients 
will be further examined with FFRCT, 82Rb-PET, 3T CMRI, and ICA with FFR, coronary flow reserve 
(CFR), Index of Microvascular Resistance (IMR) and QFR assessment (Figure 1). The numbers presented 
are based on the newly completed Dan-NICAD 1-trial.[11] Based on previous experience, the inclusion rate 
is expected to be 70%, and the patient inclusion is expected to be completed within 28 months. 
All perfusion scans will be conducted at dedicated regional hospitals, CMRI at Regional Hospital Central 
Jutland and 82Rb-PET at Hospital Unit West. FFRCT will be analyzed by an independent corlab following an 
abnormal coronary CTA. ICA and invasive measurements will be conducted at Aarhus University Hospital.  
 
2.2 Randomization and blinding procedure  
If the patient has obstructive CAD at coronary CTA, a random allocation sequence stratifying for sex and 
inclusion site is created using a standard computerized random-number generator in regards to randomizing 
patients to undergo either 82Rb-PET or CMRI examination first. The physicians performing coronary CTA, 
82Rb-PET, CMRI or ICA-FFR are initially blinded to the results of all other diagnostic test. The physicians 
performing FFRCT are not blinded to coronary CTA results.  In a second analysis, when all coronary CTA, 
82Rb-PET, CMRI or ICA-FFR analyses have been made, the physicians performing 82Rb-PET and CMRI 
analyses are unblinded to coronary CTA, but not ICA, results. Results are re-calculated with information on 
coronary CTA findings and symptoms in order to mimic the clinical situation. The unblinded procedures are 
secondary investigations.  
2.3 Study population 
Based on a clinical assessment in an outpatient cardiology setting, the study cohort consists of patients with 
low or intermediate pre-test probability of CAD referred for cardiac evaluation by coronary CTA. 
Determination of low and intermediate pre-test probability is clinically supported of the updated Diamond-
Forrester score.[19] Inclusion and exclusion criteria are listed in Table 1. All enrolled patients are 
systematically interviewed and undergo an acoustic CAD-score examination alongside blood sampling 
stored in a biobank and coronary CTA.  
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2.4 Biobank 
From all participants consenting to the study, five blood samples are drawn prior to coronary CTA contrast 
administration. Within two hours, three of the samples are centrifuged and processed into EDTA plasma, 
Heparin plasma, and serum, which are aliquoted into individual matrix tubes and placed at minus 20 degree. 
Two 4ml EDTA blood samples are placed directly in the freezer for later extraction of genomic DNA. All 
biospecimens are transported on dry ice to the Dan-NICAD biobank at Department of Biomedicine, Aarhus 
University, where all samples are stored at minus 80 degree. After extraction of genomic DNA, the samples 
will undergo array genotyping and whole genome sequencing for investigation of common and rare 
variations associated with CAD and sub-phenotypes recorded in the trial.  
2.5 CADScor®System 
The CADScor®System (Acarix A/S, Denmark) is a device using acoustic analysis performed just prior to 
coronary CTA examination and blood sampling. Heart sounds characteristic to CAD including turbulent 
blood flow caused by coronary stenoses are recorded using a microphone mounted at the 4th intercostal 
space just left to the sternum using a dedicated patch. The CAD-score examination is performed in 
accordance with the manufactures´ guidelines (figure 2). Using a fully automated algorithm version 3.1, a 
CAD-score is immediately calculated by the device following the acoustic examination. The algorithm has 
been adjusted compared to previously published results [9] to increase the sensitivity. A CAD-score > 20 is 
considered abnormal (table 2). 
2.6 Imaging 
2.6.1 Cardiac computed tomography angiography 
Patient preparation – coronary CTA 
According to the clinical routine of the radiology department, patients are instructed to abstain from all 
substances and drugs containing caffeine for at least 24 hours prior to the coronary CTA examination. 
Patients receive 50-100 mg metoprolol, 50-100mg atenolol or 7.5-15 mg ivabradin the night before and two 
hours prior to coronary CTA to reduce the heart rate <65 beats per minute (BPM). If not contraindicated, 
patients with persistent HR>65 BMP receive 2.5-20 mg metoprolol tartrate intravenously. Just prior to the 
coronary CTA, all patients receive 0.8 mg of sublingual nitroglycerin. The procedure is in accordance with 
normal clinical routine.   
Imaging protocol - CTA 
CTA examination is performed using a 320 multi-slice volume CT scanner (Aquilion One, Toshiba Medical 
Systems, Japan and Siemens Flash, Siemens Healthcare, Germany) using prospective electrocardiogram 
(ECG) triggering. The CTA protocol is schematically shown in figure 2. The coronary CTA includes 2 
different acquisition protocols: 1) A non-enhanced examination and 2) A contrast-enhanced cardiac 
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examination. Following the enhanced examination, data are reconstructed in the cardiac diastolic phase at 
70-99% of the RR interval. If the patient has severe tachycardia, the diastolic scan can be combined with the 
systolic phases, typically phase 40%. The best phase at slice thickness 0.5 mm is transferred to a dedicated 
workstation (Vitrea Advanced Workstation, Vital Images, Minnetonka, MN, USA or Syngo.Via, Siemens 
Healthcare, Erlangen, Germany). 
 
Imaging analyses - CTA 
All coronary CTA analyses are performed by an experienced cardiologist. An Agatson calcium score is 
initially calculated using dedicated workstations. Using the 18-segment model described by the Society of 
Cardiovascular Computed Tomography, the luminal diameter stenosis is evaluated in each segment of the 
coronary tree.[20] Visually assessing and quantifying coronary lesions, the severity of coronary stenosis are 
classified as: no stenosis—0 % diameter reduction (≈ 0 % area reduction); mild stenosis—1 to 29 % diameter 
reduction (≈ 1 to 50 % area reduction); moderate stenosis—30 to 49 % diameter reduction (≈ 50 to 69 % area 
reduction); and severe stenosis—50 to 100 % diameter reduction (≈ 70 to 100 % area reduction). The criteria 
for an abnormal coronary CTA are shown in table 2. 
FFRCT are performed using dedicated software. FFRCT values in the major epicardial arteries (left main, left 
anterior descending, left circumflex, and right coronary; including side branches). The criteria for an 
abnormal FFRCT are outlined in table 3. 
 
2.6.2 Positron emission tomography  
Patient preparation - PET 
According to the clinical routine of the nuclear department, patients are instructed to abstain from all 
substances and drugs containing caffeine for at least 24 hours prior to the 82Rb-PET examination.  
 
Imaging protocol and image reconstruction – PET 
The 82Rb-PET protocol is schematically shown in figure 2. 82Rb-PET data is obtained in list mode with a 
Siemens Biograph mCT/64 PET-scanner (Siemens Healthcare, Knoxville, Tennessee, USA). The 
participants undergo two image acquisitions, 5 minutes each; the first at rest and the subsequent during 
hyperemia induced by adenosine. Criteria for and insurance of sufficient adenosine stress are listed in table 
3. 
 
Imaging analysis – PET 
Imaging analyses are performed by an independent core lab at Aarhus University Hospital, Denmark blinded 
for additional patient information and results. The transaxial summed, gated and dynamic 82Rb-PET 
perfusion images are automatically reoriented into short-axis, vertical and horizontal long-axis slices using a 
commercially available software (QPET 2015), Cedars-Sinai Medical Center, Los Angeles, California).[21]  
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The quality of the stress and rest images is evaluated semi-quantitatively on a visual scale from 1 to 3 (1:  
good image quality with no artifacts; 2: moderate image quality, acceptable for clinical or research diagnosis; 
3: poor image quality, and diagnosing is impossible due to severe artifacts). 
For regional analysis, the recommended 17-segment American Heart Association model will be used.[22] 
Firstly, the summed perfusion images produced 150-300 seconds after 82Rb infusion are analyzed. Segmental 
perfusion scores based on the average defect severity in a given segment  is produced by the software and 
adjusted by the expert reader (0 = normal; 1= mildly abnormal; 2 = moderately abnormal; 3 = severely 
abnormal; 4 = absent).[23] From the segmental scores, Summed Stress Score (SSS), Summed Resting Score 
(SRS) and Summed Difference Score (SDS) are calculated and reported for vascular territories, regions and 
the entire (global) left ventricular myocardium. An abnormal 82Rb-PET scan is defined as (1) an SDS ≥ 4 
involving ≥ 2 contiguous segments (reversible ischemia) and ≥ 1 segment with a stress severity score ≥ 2; (2) 
an SRS ≥ 4 involving ≥ 2 contiguous segments and ≥ 1 segment with a stress severity score ≥ 2 (irreversible 
ischemia); (3) an SSS ≥ 4 involving ≥ 2 contiguous segments and ≥ 1 segment with a stress severity score ≥ 
2 (combination of reversible and irreversible ischemia, mixed ischemia); 4) poor image quality (score 3, non-
diagnostic). From the gated images obtained 150-300 seconds after 82Rb infusion, left ventricle ejection 
fraction during rest and hyperemia and transient ischemic dilation (mean volume hyperemia / mean volume 
rest) is calculated.  
Secondly, PET-derived myocardial blood flow (MBF) is calculated by the QPET software from images 
acquired 0-120 seconds after the 82Rb infusion using the model proposed by Lortie et. al.[24] MBF and MBF 
reserve (MFR) defined as MBF during maximal hyperemia divided by MBF at rest will be reported for the 
three coronary territories. Moreover, segmental coronary flow during stress and rest will be registered.  
After the blinded analysis described above has been performed, the 82Rb-PET images are re-evaluated 
together with knowledge of patient characteristics and information from CTA (anatomy of coronary vessels 
and possible stenosis).   
The criteria for an abnormal 82Rb-PET are outlined in table 3. 
 
2.6.3 Cardiac Magnetic Resonance Imaging  
Patient preparation - CMRI 
According to the clinical routine of the radiology department, patients are instructed to abstain from all 
substances and drugs containing caffeine for at least 24 hours prior to the CMRI examination.  
 
Imaging protocol and image reconstruction – CMRI 
The CMRI scans are conducted using a 3.0T MRI system (Siemens Skyra, Software release E11A, Siemens 
Healthcare GmbH, Germany) using the Body 18 and Spine 32 receive coils. Blood pressure, distal oxygen 
saturation and a vector-ECG will be monitored continuously during the examinations using a MedRad® 
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Veris® monitoring system (Bayer Healthcare LCC, USA). All sequences are ECG gated, while motion 
artifacts are minimized by breath-holding. Series of MRI scans are included to assess information regarding 
cardiac morphology, function, perfusion and viability state of the myocardium using late gadolinium 
enhancement (LGE). 
 
The CMRI protocol is schematically shown in figure 2. Cardiac morphology will be evaluated from axial and 
sagittal 2D image series covering the entire heart using a navigator gated single-shot echo-planar fast spin 
echo sequence (HASTE: Half-Fourier Acquisition Single-shot Turbo Spin-Echo).  
Hyperemia will be induced using a continuous venous infusion of adenosine. Criteria for and initiatives to 
sufficient adenosine stress are listed in table 1. Rest perfusion scans will be performed after pharmacological 
stress washout (at least 10 minutes) using the same sequence parameters as for the stress perfusion. 
Gadolinium contrast agent (Gadovist®, Bayer Schering Pharma AG, Germany) will be injected during stress 
and rest using a dual-bolus method in order to minimize saturation effects during first-pass in the arterial 
input function.[25] The dual-bolus method consists of the injection of a 10% diluted pre-bolus, followed by a 
main bolus of neat contrast agent.  
  
Imaging analyses - CMRI 
CMRI analyses are carried out in an independent core lab blinded for additional patient information and 
results. Image quality regarding artefacts and image homogeneity are scored qualitatively using a scale from 
1-3 (1 = good image quality, no significant artifacts; 2 = moderate image quality, with significant artifacts 
but overall diagnostic image quality; 3 = severe artifacts with poor/non-diagnostic image quality).  
Several volume measurements are carried out including left ventricular end-diastolic volume (LVED), left 
ventricular end-systolic volume (LVESV), left ventricular stroke volume (LVSV), left ventricular ejection 
fraction (LVEF) and left ventricular mass. 
Regional wall motion abnormalities will be scored using a scale from 1-5: 1 = normal, 2 = mild hypokinesia, 
3 = severe hypokinesia, 4 = akinesia, and 5 = dyskinesia.  
Myocardial perfusion will be evaluated both qualitatively and quantitatively. Qualitative (visual) perfusion 
analysis will be are carried out using the standard American Heart Association model for left ventricular 
assessments.[22] Stress-induced perfusion defects will be defined on visual assessment as a delayed wash-in 
of contrast persisting for at least five dynamic cardiac cycles in ≥2 contiguous segments compared with 
normal remote myocardium. Each AHA segment will be sub-divided into an endocardial and epicardial half, 
resulting in a total of 32 segments to allow an accurate calculation of ischemic burden. Moreover, the 
presence of LGE will be reported. The criteria for an abnormal CMRI are shown in table 3. 
 
Quantitative perfusion analyses will be performed in collaboration with King’s College London, UK using 
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previously validated software.[26-29] The analyses will be performed by Fermi-constrained deconvolution 
according to the previously described methods, in which time-signal intensity curves for the tissue impulse 
response function, h(t), were fitted to the Fermi function using a Marquardt-Levenberg nonlinear least-
squares algorithm according to the following analytical expression: 
 
by letting k, R, and τ0 vary and keeping τd fixed. In the preceding equation, u(t - τd) is the unit step function. 
The τd accounts for the delay time between the appearance of the signal in the left ventricular blood pool and 
myocardial region of interest (ROI); τ0 characterizes the width of the shoulder of the Fermi function during 
which little or no contrast agent had left the ROI. R is the index of contrast agent influx parameter, and k 
represents the decay rate of h(t) due to contrast agent washout. Using the preceding equation, myocardial 
blood flow (MBF) estimates are calculated as h(t) at t = 0. Myocardial perfusion reserve (MPR) will be 
calculated as the ratio between stress and resting MBF estimates. The presence of ischemia evaluated with 
quantitative perfusion analyses will be defined as regions with MPR <1.5, according to previously validated 
criteria. In a separate analysis, CMRI analyses are compared to the coronary vessels´ anatomy and possible 
stenoses exposed during CTA and patient characteristics. 
 
2.6.4 Invasive coronary angiography and invasive physiological examination – ICA, FFR, CFR, QFR 
Patient preparation 
According to the clinical routine of the cardiac department, patients are instructed to abstain from all 
substances and drugs containing caffeine for at least 24 hours prior to the ICA examination.  
 
Cardiac catheterization protocol 
Invasive coronary angiography 
All diagnostic ICAs are performed at Aarhus University Hospital according to present clinical guidelines 
through a femoral or radial access. Before acquisition of the ICA, the operator administrates 250 μg of intra-
coronary nitroglycerine. The ICA protocol is schematically shown in figure 2. All lesions with a diameter 
stenosis of 30-90% by visual estimate and a reference diameter of > 2mm are considered for physiological 
assessment. Angiographic acquisitions are performed at 15 frames per second in at least two projections 
more than 25 degrees apart allowing for 2D quantitative coronary angiography (QCA) and QFR analysis. 
Coronary artery overlap, foreshortening, zooming and planning is avoided if possible. All vessels are 
visualized in their full length if possible.  
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Patient preparation for physiological examination 
Anticoagulation (5,000 IU heparin) is administrated prior the pressure measurement. The pressure-wire 
(PressureWire X Guidewire, Abbott Chicago, USA) and CoroFlow systems are used according to 
manufacture instructions for use. The pressure wire is advanced to the tip of the guiding catheter to equalize 
the pressure readings.    
Resting Pd/Pa and average mean resting transit time    
The wire is advanced distal to all lesions in the vessel of interest and the wire-position is documented. 
Resting Pd/Pa is recorded as a minimum of 10 seconds with a stabilized Pa/Pa value after checking the 
pressure-curves. Next, 3 ml of room-temperature saline is injected rapidly by hand 3 times to record mean 
transit time at baseline while the coronary system is not affected by adenosine.  
 
Fractional flow reserve, coronary flow reserve and index of microvascular resistance 
Hyperemia is induced using a 1 mg/mL concentration of adenosine at 140 ug/min/kg and the infusion rate is 
increased to 200 μg/L/min if a stable FFR value is not achieved. When maximum hyperemia is achieved, 
three boluses of saline are injected to obtain hyperemic thermodilution curves for hyperemic mean transit 
time calculation. Coronary flow reserve (CFR) and the index of microvascular resistance (IMR) are instantly 
presented during the procedure. CFR is defined as the mean resting transit time by the mean hyperemic 
transit time. IMR is defined as the mean distal pressure multiplied by the mean hyperemic transit time. 
Routine checks are made to ensure that ‘drift’ does not occur after the recordings. Absolute drift value of ≤ 
±0.02 is accepted.  
 
Post-procedural physiological examination 
Resting Pd/Pa, FFR, IMR and CFR are measured following PCI treatment of diseased vessels. QCA-
projections are repeated for core-lab QFR computation of vessels treated with PCI.  
 
Image analysis - ICA 
All physiologic core-lab analyses are performed blinded to the patient´s CAD score, CTA, CMRI, and 82Rb-
PET examination. Invasive physiology analysis (Coroventis Research AB, Uppsala, Sweden) is performed in 
a suited corelab (Institute of Clinical Medicine, Aarhus University, Denmark). 2D-QCA is performed in an 
independent core lab (ClinFact, Leiden, The Netherlands).  
The criteria for an abnormal ICA are shown in table 2. 
Quantitative flow ratio analysis 
QFR and 3D-QCA core-lab analyses are performed in a core-lab setting (Aarhus University Hospital, 
Skejby, Denmark) using the latest version of the software (QAngio XA 3D, Medis medical imaging system, 
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Leiden, The Netherlands). The methodology and technical specifications were recently published.[16] 
Analysis is performed according to standard operating procedures.[30] QFR ≤0.80 is used as diagnostic cut-
off value.  
2.7 Follow-up 
The cohort is followed for a period of 10 years after the coronary CTA examination. Data are extracted from 
the Civil Registration System (CRS) and the National Patient Registry (NPR). Data are adjudicated by look-
up in the electronic patient file and verified by an adjudication committee. The purpose is to investigate the 
prognostic values of the CADScor®System and second second-line investigations following coronary CTA. 
Data recorded are: mortality, cardiovascular events, cardiac disease, revascularization treatment and medical 
treatments and comorbidity. Cases are electronically recorded using the patient specific electronical record 
with additional information on biochemistry, medication and other examination results.  
 
2.8 Data collection and recordings 
All study data are recorded in a secure web-based electronic case record form ((eCRF) – Research Electronic 
Data Capture (REDcap®)[31]) that enables logging of all data entries. The CAD-score measurement, patient 
interview, and blood samples are obtained by trained and skilled study nurses. All investigators have access 
to the eCRF. However, physicians performing corelab analyses have limited access in regards of blinding 
procedures. Data collected and registered in the dedicated eCRF are listed in Addendum. The study is 
monitored according to ICH-GCP (ICH Harmonized Tripartite Guideline for Good Clinical Practice). 
 
2.9 Endpoints and statistical analysis  
Data analysis and reporting will follow the Standard Protocol Items: Recommendations for Interventional 
Trials (SPIRIT) and Standard for Reporting Diagnostic Accuracy Studies (STARD) guidelines. All 
demographic and baseline characteristics will be presented and analyzed using appropriate statistical 
methods.  
 
2.9.1 Analyses of CADScor® 
Our first main objective is to show superiority for the CADScor®System compared to the updated Diamond-
Forrester score[19] for the area under the receiver-operator characteristics curve for detection of CAD. The 
reference standard used is anatomically significant coronary stenosis assessed by ICA-2D-QCA (≥50% 
diameter stenosis). Patients are categorized as having I) obstructive CAD: ≥50% diameter stenosis by ICA-
2D-QCA, or II) no obstructive CAD: <50% diameter stenosis by ICA-2D-QCA or negative coronary CTA. 
The diagnostic performance is evaluated on a patient level as ROC-AUC with the CAD-score as a 
continuous variable. Similarly, calculations are made using hemodynamically significant obstructive CAD 
with ICA-FFR as the reference standard. Secondary, the diagnostic performance is reported with sensitivity, 
specificity, positive predicative value, negative predicative value, where the CAD-scores are dichotomized 
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with a positive value above 20. 
All analyses will be performed with CAD-scores calculated with algorithm version 3.1. Furthermore, 
analyses may be performed with further developed algorithms using sound files collected in the study.  
2.9.2 Analysis of value of non-invasive imaging 
The second main objective of this study is to investigate and compare the diagnostic precision of 82Rb-PET 
and 3T CMRI as secondary examinations following coronary CTA where obstructive CAD cannot be 
excluded using ICA-FFR as reference standard.   
The diagnostic precision of 82Rb-PET and CMRI is evaluated by sensitivity, specificity, positive and 
negative predictive value, diagnostic accuracy and likelihood ratios. Comparison of 82Rb-PET and CMRI 
sensitivity, specificity, positive and negative predictive value is tested using McNemar´s test and a weighted 
generalized score statistic for comparison of predictive values of diagnostic tests.[32] The reference standard 
used is invasive FFR≤0.80, and tests are made on both patient and coronary vessel level.  
Further, we will evaluate 1) the diagnostic accuracy of FFRCT compared to 82Rb-PET and CMRI 2) the 
impact of using additional CFR and IMR on the FFRCT, 82Rb-PET and CMRI related diagnostic accuracy, 3) 
the diagnostic precision of CMRI absolute perfusion 4) the diagnostic precision of CMRI dyssynchrony 
analysis of coronary stenoses. 
 
2.9.3 Analysis of QFR performance 
The third main objective is to compare the diagnostic performance of QFR with FFR using 82Rb-PET as 
reference for ischemia. Diagnostic performance of QFR is measured and compared to FFR for accuracy, 
ROC-AUC, sensitivity, specificity, negative predictive value, positive predictive value, positive likelihood 
ratio and negative likelihood ratio with 82Rb-PET as reference. The same comparisons are made using CFR 
with a cut-point of 2.0 as reference standard. Time-frame count derived estimated contrast flow velocity is 
compared to mean transit time estimated by thermodilution technique during resting and hyperemic 
conditions.  Subgroup analyses are performed for patients grouped by diagnostic match or mismatch between 
FFR and QFR; on 1) numerical differences in CFR and IMR between cases with matched vs mismatched 
FFR and QFR, 2) agreement of the two groups with 82Rb-PET and separately with 3T CMRI, 3) stenosis 
morphology as assessed with 2D and 3D-QCA compared for the two groups. Diagnostic mismatch is defined 
according to the predefined cut-point of 0.80 and in a separate analysis by an absolute QFR-FFR difference 
>0.05. 
 
For all statistical analyses, a two-sided p value < 0.05 is considered statistically significant, and 95 % 
confidence intervals are reported when appropriate. Statistical analysis is performed using dedicated 
statistical software (STATA, StataCorp, College Station, TX, USA). 
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2.10 Sample size  
Based on the DAN-NICAD 1 trial, we expect that approximately 2,000 patients are to be included and 
undergo coronary CTA. Following coronary CTA, we expect that 460 (23%) patients in whom coronary 
stenosis cannot be excluded are eligible for continuing to the perfusion examinations and ICA part of the 
trial. We expect 80% to complete both CMRI, 82Rb-PET and undergo ICA examination. By including 2,000 
patients, we are able to evaluate the predictive validity parameters (sensitivity, specificity, positive and 
negative predictive values) with a minimum of 6% absolute precision on both sides for the expected 
sensitivity (80%) and specificity (80%) for both CMRI and 82Rb-PET at a disease prevalence of 50% at 
CMRI and 82Rb-PET. 
To show statistically significant superiority for the AUC for the CADScor®System compared to the 
AUC for the updated Diamond-Forrester score [19]for detection of CAD it is assumed that I) the AUC for 
CAD-score is 0.72 and the AUC for the Diamond-Forrester score is 0.66, II) the covariance between the 
CAD-score and the Diamond-Forrester score is 0.46, III) the CAD prevalence is 10%. Based on these 
assumptions a minimum of 157 CAD patients and 1413 patients without CAD are to be included in the 
analysis for the primary CAD-score objective. 
QFR has not previously been compared to non-invasive perfusion scans. Using recent data that compared 
FFR to 82Rb-PET, we use a sensitivity and specificity for 82Rb-PET derived relative flow reserve of 0.83 and 
0.84, respectively.[33] We accept a lower confidence interval limit of 0.80, and a two-sided confidence 
interval is used. With an expected dropout rate of 0.20, alpha=0.05 and a rate of true positives of 30 % in the 
population with successful FFR assessment (flow limiting stenosis prevalence), we estimate a need of 341 
patients with 82Rb-PET scans for sensitivity analysis and 139 patients with 82Rb-PET scans for specificity 
analysis.  
 
2.11 Ethical considerations  
The study follows the principles outlined in the Declaration of Helsinki and ISO 14155:2011. The study´s 
additional radiation exposure in regards of the 82Rb-PET examination increases the cumulated risk over a 
life-time of dying from cancer from approx. 25% to 25.1%. Patients participate in the study only after 
providing informed written consent. There is a small risk of incidental findings in this study. According to 
the Danish research ethical guidelines for genome research, an expert panel will be formed in the case of an 
incidental finding and clinical guidance will be provided by trained clinical geneticists within the field of that 
particular disease. The study was registered at ClinicalTrials.gov (Identifier; NCT03481712).  
2.12 Disclosure  
The study was supported by Acarix A/S. Otherwise, the authors are solely responsible for the design and 
conduct of this study, all study analyses, the drafting and editing of the paper and its final contents. 
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2.12 Funding  
The study was supported by Aarhus University, Health Research Fund of Central Denmark Region, and Acarix A/S. 
3. Discussion 
Dan-NICAD 2 is a multi-purpose study assessing 1) the diagnostic performance of the CADScor®System, 2) 
the diagnostic benefit of performing perfusion tests and FFRCT after positive coronary CTA, and 3) 
comparing QFR with invasive FFR using 82Rb-PET as reference. 
Coronary CTA has proven to be a valid tool for ruling out CAD in patients with a low to intermediate pre-
test probability of CAD.[34-36] However, the low positive predictive value of coronary CTA alone causes 
‘unnecessary’ downstream testing with e.g. ICA where patients are not revascularized. The need for more 
specific strategies for non-invasive diagnostic work-up of patients with suspected CAD was demonstrated in 
a large study comprising 398,978 patients in whom elective cardiac catheterization showed obstructive CAD 
in only 38%.[37] The diagnostic accuracy of SPECT and 1.5 CMRI as secondary non-invasive CAD 
examinations was investigated in the Dan-NICAD 1 trial and showed in general a low sensitivity for 
diagnosing significant stenosis as defined by FFR≤0.80.[11, 12]  
The Dan-NICAD 2 study aim to test whether unnecessary ICA examination can be avoided by performing 
updated novel secondary perfusion imaging tests such as 82Rb-PET and 3T CMRI or FFRCT in patients, 
where coronary CTA examination does not exclude CAD. In these patients, the Dan-NICAD 2 study also 
applies advanced invasive measures such as CFR, IMR and QFR to allow for a more precise invasive 
assessment of the lesions. 
To date, several acoustic detection systems are under development for CAD investigation.[7] We previously 
found that sound-based stratification of patients with the CADScor®System is comparable to clinical risk 
scores alone.[38] Further, in the DAN-NICAD 1 study we validated an automatic CADScor®System 
software algorithm including both sound-based features and clinical risk factors, which increases the 
diagnostic accuracy compared to clinical risk stratification alone. The higher specificity of the CAD-score 
compared to the updated Diamond-Forrester score also provides a relevant reclassification potential. With a 
negative predictive value of 96%, this new acoustic rule-out system could potentially supplement clinical 
assessment to guide decisions on the need for further diagnostic investigation.[9] In the DAN-NICAD 2 trial, 
we will evaluate the latest version of the software and potentially further developed algorithms. Populations 
change over time, and the current trends point towards a lower prevalence in populations undergoing non-
invasive testing. This might change the weights of the different components, such as gender and age in the 
optimal algorithm. In developing an optimal algorithm, the false negative patients at coronary CTA is a 
limitation in the current study. However, the impact of this potential work-up bias is considered low due to 
the high sensitivity of the coronary CTA. 
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Myocardial perfusion imaging with PET-technology enables non-invasive information of myocardial 
perfusion during rest and pharmacologically induced hyperemia by using a radioactive isotope taken up by 
vital cardiomyocytes proportionally to blood supply. Compared to SPECT, PET technique provides a higher 
image resolution, quantification of perfusion and causes less radiation exposure.[39] Previous studies have 
investigated the diagnostic accuracy of 82Rb-PET for myocardial perfusion. Some of these studies are 
retrospective and influenced by referral biases, and some are limited by applying ICA luminal diameter 
stenosis as reference standard. Not using ICA-FFR as reference standard, previous studies compare 
functional and anatomical tests, which can be challenging.[5, 40] However, compared to SPECT, studies 
indicate that 82Rb-PET has higher sensitivity with similar specificity in predicting CAD. A recent study using 
ICA-FFR as reference standard found 82Rb-PET with a sensitivity of 87% and a specificity of 95%.[41] 
 
3T CMRI is a non-invasive, non-radioactive, high resolution examination. In addition to coronary perfusion, 
3T CMRI enables investigation of the general cardiac function including possible valve diseases and scar 
formation. CMRI has shown high sensitivity and specificity when assessing coronary stenoses.[42-44] As 
with 82Rb-PET, investigations of CMRI accuracy has primarily been conducted with ICA diameter stenosis 
as reference standard.[5, 45-48] However, using ICA-FFR as reference standard, a recent metaanalysis found 
CMRI having an average sensitivity of 90% and a specificity of 87%.[49] This metaanalysis, however, only 
included 3 out of 14 studies using 3T CMRI.  
Experimental software is currently being developed at St. Thomas Hospital, King´s College, London. The 
software enables investigation of quantified myocardial perfusion and perfusion dyssynchrony from CMRI 
images.[28, 50] During Dan-NICAD 1, our research group has initiated a collaboration with St. Thomas 
Hospital, and the software will be tested in Dan-NICAD 2 by further evaluating the diagnostic accuracy 
compared to 82Rb-PET and invasive FFR.   
 
The use of image-based modeling and computational fluid dynamics enables assessment of coronary blood 
flow and pressure from already existing coronary CTA images.[15, 51-53] The technique is known as FFRCT 
and has in blinded trials shown high diagnostic performance compared to ICA-FFR.[15, 52, 53] Although 
results are promising, FFRCT´s clinical utility is to our knowledge unknown.  
Conventional coronary CTA enables anatomical CAD assessment, and as demonstrated in the PROMISE 
and SCOT-HEART trails, coronary CTA as frontline examination increases the diagnostic accuracy 
compared to non-invasive functional tests in patients with stable CAD.[54, 55] As outlined, conventional 
coronary CTA, however, tends to overestimate stenoses’ severity and their functional implication.[3, 56] The 
discrepancy between the anatomical and functional tests might be tackled using combined information of 
anatomy and physiology in terms of FFRCT.  
Studies upon head-to-head comparison of FFRCT and advanced myocardial perfusion examinations lack. In a 
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single-center, non-randomized, observational study, Nørgaard et al. [57] found the introduction of FFRCT to 
decrease ICA utilization and increase ICA diagnostic yield compared to 82Rb-PET. The ReASSESS study 
found FFRCT and SPECT with similar diagnostic accuracy, but FFRCT yielded higher sensitivity.[58] 
Currently, the results from the CREDENCE trial are awaited.[59]  
NICE currently recommends HeartFLOW FFRCT analysis for patients with stable chest pain.[1] However, 
although FFRCT is a very promising technique, it has not been evaluated for long term results. Furthermore, 
not all CT scans has sufficient quality to enable FFRCT evaluation, and other techniques must be used for 
these patients. 
 
The severity of coronary calcification has an impact on the agreement between coronary CTA and ICA when 
assessing obstructive lesions at the individual coronary segment level, and many patients with non-diagnostic 
coronary CTA have intermediate coronary stenoses.[3, 60] Hence, a population based on non-diagnostic 
coronary CTA have relatively few patients at the extremes (no stenosis; very severe stenosis), and a 
possibility is that the Dan-NICAD 2 study will find no difference in the diagnostic accuracy between 82Rb-
PET, 3T CMRI and FFRCT. However, in the Dan-NICAD 1 population [11], 40% of the patients with 
“coronary CTA stenosis” underwent revascularization due to treatment requiring stenosis. As the inclusion 
criteria for this trial is similar with Dan-NICAD 1, we expect about the same occurrence of need for 
revascularization. 
 
Symptoms of angina are ultimately caused by oxygen supply-demand mismatch caused by diminished blood-
flow to the myocardium. However, FFR is a pressure-only index used as surrogate for coronary flow 
measurements.[61] Recent data document that abnormal FFR values may coexist with normal coronary flow 
reserve (CFR) measurements while normal FFR can coexist with abnormal CFR measurements.[62] Hence, 
CFR and IMR may clarify potential mismatches between CMRI, 82Rb-PET and FFR measurements. Further, 
the global uptake of FFR-guided revascularization remains low.[63] This has led to the development of 
quantitative flow ratio (QFR) for a less invasive, cheaper and safer assessment of coronary artery stenosis. In 
the initial studies, QFR showed good agreement to FFR. However, the approximately 20 % disagreement has 
not yet been evaluated using a third ischemia test as reference standard. The results of Dan-NICAD 2 may 
help determine whether disagreement between FFR and QFR is caused by methodological errors, natural 
variation or if one test may be superior to the other. 
4. Perspective  
The results of the Dan-NICAD 2 study are expected to contribute to the improvement of diagnostic strategies 
for patients suspected of CAD in three different steps; risk-stratification prior to coronary CTA, diagnostic 
strategy after coronary CTA and invasive wireless QFR analysis as an alternative to ICA-FFR. 
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5. Study status  
The study is ongoing. The first patient was enrolled on January 24th 2018. Enrolment completion is expected 
in June 2020.  
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Figure 1: Dan-NICAD 2 patient flowchart. 
Numbers (n) in the figure are the estimated flow in patients. Abbreviations: CAD, coronary artery disease; 
CTA, coronary computed tomography angiography; FFRCT: CT-derived fractional flow reserve; CMRI, 
cardiac magnetic resonance imaging; 82Rb-PET, rubidium-82 positron emission tomography; ICA-FFR, 
invasive coronary angiography with fractional flow reserve; QFR, quantitative flow reserve; IMR, index of 
microvascular resistance; 2D QCA, two-dimensional quantitative coronary angiography. 
 
Figure 2: Image modalities and examination set-up in Dan-NICAD 2 study. 
Abbreviations: ECG, electrocardiogram; CAD, coronary artery disease; CTA, coronary computed 
tomography angiography; FFRCT: CT-derived fractional flow reserve; CMRI, cardiac magnetic resonance 
imaging; 82Rb-PET, rubidium-82 positron emission tomography; ICA-FFR, invasive coronary angiography 
with fractional flow reserve; CFR, coronary flow reserve; IMR, index of microvascular resistance, QFR, 




• The poor positive predictive value of coronary CT scanning facilitates unnecessary invasive 
angiographies. An optimized diagnostic CAD algorithm would be preferable.   
 
• The Dan-NICAD 2 is a prospective, multicenter, cross-sectional study including 2,000 patients with 
low to intermediate pre-test probability of CAD. Patients are tested using a rule-out sound-based 
device before clinical coronary CTA. If the coronary CTA does not rule-out CAD, patients are 
examined with 3T CMRI, 82Rb-PET, FFRCT, ICA with FFR, CFR, IMR and QFR measurements. 
 
• No previous study has compared head-to-head the more advanced myocardial perfusion 
examinations and FFRCT as second-line investigations following a positive coronary CTA with 
ICA-FFR as reference. Moreover, the study will analyze the differences between FFR and QFR 
using gold standard nuclear technique 82Rb-PET as reference.  
 
• The results of the Dan-NICAD 2 study are expected to contribute to the improvement of diagnostic 
strategies for patients suspected of CAD in three different ways; 1) evaluate risk-stratification prior 
to coronary CTA using acoustic detection, 2) evaluate diagnostic strategies after coronary CTA and 
3) evaluate invasive wireless QFR analysis as an alternative to ICA-FFR. 
 
Table 1: Study enrollment criteria 
Criteria for inclusion 
- Patients with low to intermediate pre-test probability of CAD with an indication for CCTA  
- Qualified patients who have signed a written informed consent form 
 
Criteria for exclusion 
Demography and co-existing morbidity specific 
- Age below 30 years  
- Acute coronary syndrome and unstable angina pectoris 
- Previous revascularization or known ischemic heart disease 
- Patients having a heart transplantation, a mechanic heart, or mechanical heart pump. 
- Patients not able to breath-hold (COPD/asthma) 
 
CADScor®System specific 
- Damaged skin in the area for application of the CADScor®Patch 
- Known allergy to polyacrylate adhesives 
- Significant scar tissue or bodily deformation in left IC4 (Left 4th Inter Costal region) 




- Pregnant women, including women who are potentially pregnant or lactating   
- Reduced kidney function, with an estimated glomerular filtration rate (eGFR) < 40 mL/min  
- Allergy to X-ray contrast medium   
CMRI and PET: 
- Unstable CAD at CCTA. 
- Contra-indication for adenosine (severe asthma, advanced AV block, or critical aorta stenosis) 
- Contra-indications for MRI (implanted medicinal pumps or nerve stimulators, magnetic foreign objects in sensitive areas, i.e. the eye 
- Patients having an ICD or pacemaker, a cochlea implant, or metal clips evaluated by the including physician  













Table 2: Definitions of abnormal examinations 
Blinded analysis  











Na Significant reduction in the isotope distribution in 
> 10% of the entire myocardium of the left 
ventricle during stress (SSS≥4 in ≥ 2 contiguous 
segments)  
and/or 
locally reduced blood flow <2 ml/g/min during 
adenosine stress  
or 
Myocardial flow reserve ≤1.8 x global rest blood 
flow corrected to rate-pressure product 8000 
and/or 
Transient ischemic dilation ratio >1.13 + stress-EF 
< rest-EF 
or 




Significant perfusion defect, either 
subendocardial or transmural signal changes, 
in ≥ 2 contiguous segments 
and/or 
LGE in ≥ 2 contiguous segments 
and/or 
Wall motion abnormalities in ≥ 2 contiguous 
segments  
or 
Non-evaluable examination due to low 
examination quality 
High-grade stenosis (> 90 % 
diameter stenosis) by visual 
assessment  
or 
ICA-FFR ≤ 0.80 in a vessel with a 
diameter stenosis of 30-90% 
or 
QCA-based diameter stenosis (≥50 
% diameter) if ICA-FFR not 
performed due to e.g. technically 
not possible 
 
Prior knowledge analysis (Not blinded to patient data and the CCTA) 
Na Na FFRCT ≤ 0.80*Δ Significant reduction in the isotope distribution in 
> 10% of the entire myocardium of the left 
ventricle during stress (SSS≥4 in ≥ 2 contiguous 
segments) in an area of the myocardium 
corresponding to coronary stenosis at CCTA 
and/or 
locally reduced blood flow <2 ml/g/min during 
adenosine stress in an area of the myocardium  
corresponding to coronary stenosis at CCTA 
and/or 
Myocardial flow reserve ≤1.8 x global rest blood 
flow corrected to rate-pressure product 8000 
and/or 
Transient ischemic dilation ratio >1.13 + stress-EF 
< rest-EF + multivessel disease present at the 
coronary CTA 
or 
Non-evaluable examination due to low 
examination quality 
Significant perfusion defect, either 
subendocardial or transmural signal changes, 
in ≥2 contiguous segments corresponding to 
coronary stenosis at coronary CTA 
and/or 
LGE in ≥ 2 contiguous segments 
corresponding to coronary stenosis at 
coronary CTA 
and/or 
Wall motion abnormalities in ≥ 2 contiguous 
segments corresponding to coronary stenosis 
at coronary CTA 
or 





Definitions of abnormal examinations in the Dan-NICAD 2 study. *In coronary vessel ≥ 2.0 mm in diameter. Δstill blinded to patient information. Abbreviations: coronary CTA, coronary computed 
tomography angiography; CT-derived fractional flow reserve, FFRCT; CMRI, cardiac magnetic resonance imaging; 82RbPET, 82 rubidium positron emission tomography; SSS, summed stress score;; 
ICA-FFR, invasive coronary angiography with fractional flow reserve measurements.; quantitative coronary angiography, QCA; 2D QCA, two-dimensional quantitative coronary angiography; LGE, late 
gadolinium enhancement; LVEF, left ventricle ejection fraction.  
 Table 3: Sufficient adenosine stress 
 
Criteria for and initiatives to sufficient adenosine stress in the Dan-NICAD 2 study. Abbreviations: PET, positron emission tomography; CMRI, cardiac magnetic resonance imaging; ICA-FFR, invasive 
coronary angiography with fractional flow reserve measurements. 
Addendum 
Data collected during the project and registered in a dedicated eCRF:  
• Demography – age, sex, ethical origin and pregnancy test.  
• Co-morbidity. 
• Risk factors for ischemic heart disease—genetic disposition, smoking status, diabetes mellitus, hypertension, hypercholesterolemia, blood 
pressure, heart rate, weight, height, hip to waist ratio and electrocardiogram (ECG). 
• Symptoms—typical, atypical, or unspecific chest pain, New York Heart Association (NYHA) functional class, and Canadian Cardiovascular 
Society (CCS) score of angina pectoris.  
• Seattle Angina Questionnaire at baseline, and 3 and 12 months post inclusion. 
• Biochemistry – Cholesterol, glucose levels and creatinine. 
• Protein measurements on serum and plasma. 
• Blood sample test results from the biobank 
• Echocardiography—left ventricle ejection fraction (LVEF) and significant valve disease.  
• CAD score—registration of the CAD-score and recording time. 
• CCTA—scan quality, Agatston calcium score, anatomy, plaque type, degree of stenosis and radiation exposure. 
• 82Rb-PET and CMRI—Scan quality, function, response to the injection of adenosine and presence of perfusion defects. Regional and segmental 
MPR values. 
• ICA-FFR—data concerning anatomy, localization of stenosis, visual evaluation of stenosis, QCA and QFR measurements, FFR, IMR and CFR 
measurements, and whether treatment by PCI or CABG is performed.  
• Adverse Events (AE)—all adverse events occurring in the study period are registered.  
• Follow-up 10 years —mortality, myocardial infarction, revascularization, comorbidity, medicinal receipts.  
 
 
Figure 1: Patient inclusion flowchart 
 
Figure 2: Image modalities and examination set-up 
 
 
  
